Balaji Institute Of Renal Diseases Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.19 M
About Balaji Institute Of Renal Diseases
Balaji Institute Of Renal Diseases Private Limited (BIORDPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 August 2009 and has a history of 15 years and five months. Its registered office is in Allahabad, Uttar Pradesh, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹3.19 M.
Vidula Dilip and Shambhavi Chaurasia serve as directors at the Company.
Company Details
-
Location
Allahabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85191UP2009PTC037963
-
Company No.
037963
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Aug 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Balaji Institute Of Renal Diseases?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vidula Dilip
|
Director | 10-Aug-2009 | Current |
|
Shambhavi Chaurasia
|
Additional Director | 24-Mar-2014 | Current |
Financial Performance of Balaji Institute Of Renal Diseases.
Balaji Institute Of Renal Diseases Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Balaji Institute Of Renal Diseases?
In 2017, Balaji Institute Of Renal Diseases had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.19 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.17 Cr
- Corporation Bank : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Dec 2022 | Others | ₹1.69 M | Open |
| 05 Jan 2011 | Corporation Bank | ₹1.50 M | Open |
How Many Employees Work at Balaji Institute Of Renal Diseases?
Balaji Institute Of Renal Diseases has a workforce of 0 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Balaji Institute Of Renal Diseases, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Balaji Institute Of Renal Diseases's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
